Edwin A. Alvarez

Edwin A. Alvarez

Surgical Oncology | Oncology

1825 Fourth St.
Sixth Floor
San Francisco, CA 94158

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 24 publications

Phase II Trial of Ribociclib Plus Letrozole in Women With Recurrent Low-Grade Serous Carcinoma of the Ovary, Fallopian Tube, or Peritoneum: A GOG Partners Trial (GOG 3026).

Phase II Trial of Ribociclib Plus Letrozole in Women With Recurrent Low-Grade Serous Carcinoma of the Ovary, Fallopian Tube, or Peritoneum: A GOG Partners Trial (GOG 3026).

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: December 12, 2025

Efficacy of the ATR Inhibitor Ceralasertib in Patients with ARID1A-Deficient Gynecologic and Other Solid Tumor Malignancies.

Efficacy of the ATR Inhibitor Ceralasertib in Patients with ARID1A-Deficient Gynecologic and Other Solid Tumor Malignancies.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: November 06, 2025

A Technique for the Generation of Mucosal and Acral Melanoma Cell Lines.

A Technique for the Generation of Mucosal and Acral Melanoma Cell Lines.

Journal: Pigment cell & melanoma research

Published: August 22, 2025

Delay to timely treatment in locally advanced cervical cancer: insurance inequities in access to gynecologic oncology.

Delay to timely treatment in locally advanced cervical cancer: insurance inequities in access to gynecologic oncology.

Journal: American journal of obstetrics and gynecology

Published: October 01, 2024

The role of race/ethnicity and age in clinical trial knowledge among patients with gynecologic malignancy.

The role of race/ethnicity and age in clinical trial knowledge among patients with gynecologic malignancy.

Journal: Gynecologic oncology

Published: March 27, 2024

Ofranergene Obadenovec (Ofra-Vec, VB-111) With Weekly Paclitaxel for Platinum-Resistant Ovarian Cancer: Randomized Controlled Phase III Trial (OVAL Study/GOG 3018).

Ofranergene Obadenovec (Ofra-Vec, VB-111) With Weekly Paclitaxel for Platinum-Resistant Ovarian Cancer: Randomized Controlled Phase III Trial (OVAL Study/GOG 3018).

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: October 31, 2023

The past, present, and future of opioid prescribing: Perioperative opioid use in gynecologic oncology patients after laparotomy at a single institution from 2012 to 2021.

The past, present, and future of opioid prescribing: Perioperative opioid use in gynecologic oncology patients after laparotomy at a single institution from 2012 to 2021.

Journal: Gynecologic oncology reports

Published: March 13, 2023

Management of chemotherapy hypersensitivity reactions and desensitization: An SGO clinical practice statement.

Management of chemotherapy hypersensitivity reactions and desensitization: An SGO clinical practice statement.

Journal: Gynecologic oncology

Published: December 31, 2022

A Phase IB Trial of the PI3K Inhibitor Alpelisib and Weekly Cisplatin in Patients with Solid Tumor Malignancies.

A Phase IB Trial of the PI3K Inhibitor Alpelisib and Weekly Cisplatin in Patients with Solid Tumor Malignancies.

Journal: Cancer research communications

Published: January 18, 2022

Neratinib in patients with HER2-mutant, metastatic cervical cancer: Findings from the phase 2 SUMMIT basket trial.

Neratinib in patients with HER2-mutant, metastatic cervical cancer: Findings from the phase 2 SUMMIT basket trial.

Journal: Gynecologic oncology

Published: June 02, 2020

NTRK fusion cervical sarcoma: a report of three cases, emphasising morphological and immunohistochemical distinction from other uterine sarcomas, including adenosarcoma.

NTRK fusion cervical sarcoma: a report of three cases, emphasising morphological and immunohistochemical distinction from other uterine sarcomas, including adenosarcoma.

Journal: Histopathology

Published: December 16, 2019

Afatinib use in recurrent epithelial ovarian carcinoma.

Afatinib use in recurrent epithelial ovarian carcinoma.

Journal: Gynecologic oncology reports

Published: April 06, 2019

Showing 1-12 of 24

Last Updated: 09/26/2026